Journey Medical Corporati... (DERM)
Company Description
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use.
It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution.
The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation.
Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Country | United States |
IPO Date | Nov 12, 2021 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 41 |
CEO | Claude Maraoui |
Contact Details
Address: 9237 East Via de Ventura Boulevard Scottsdale, Arizona United States | |
Website | https://journeymedicalcorp.com |
Stock Details
Ticker Symbol | DERM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001867066 |
CUSIP Number | 48115J109 |
ISIN Number | US48115J1097 |
Employer ID | 47-1879539 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Claude Maraoui | Founder, President, Chief Executive Officer & Director |
Joseph M. Benesch | Chief Financial Officer & Corporate Controller |
Andrew J. Zwible | Vice President of Operations |
Dr. Lindsay Allan Rosenwald | Executive Chairman |
Jaclyn Jaffe | Senior Director of Corporate Operations |
Ramsey Alloush | General Counsel & Company Secretary |
Robert Nevin | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2025 | 10-K | Annual Report |
Mar 26, 2025 | 8-K | Current Report |
Mar 24, 2025 | 8-K | Current Report |
Mar 11, 2025 | 4 | Filing |
Mar 10, 2025 | 4 | Filing |
Mar 05, 2025 | 4 | Filing |
Feb 24, 2025 | 4 | Filing |
Feb 05, 2025 | 8-K | Current Report |
Nov 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 12, 2024 | 10-Q | Quarterly Report |